The Binding Site
Five new recombinant Epstein-Barr Virus (EBV) antigens have been added to a repertoire of broad offering of products for in-vitro diagnostic manufacturing and research applications. The EBV Capsid Antigen P18; EBV Capsid Antigen P23; EBV Early Antigen P138; EBV Early Antigen P54; and EBV Nuclear Antigen EBNA1, P72 have all been expressly designed for use as integral components within solid phase enzyme immunoassay test procedures, especially ELISA. All the antigens offered are E coli source-derived recombinant proteins which exhibit exceptional purity levels as a result of exclusive chromatographic manufacturing techniques, while demonstrating exceptional lot-to-lot consistencies and high degrees of activity and specificity. They all feature an outstanding shelf life stability claim of 10 years from the date of manufacture and are offered in a standard-sized 1.0 mg filled vial, with larger, bulk packaging configurations also available.
